EWA
AARD

EverSource Wealth Advisors’s Aardvark Therapeutics AARD Stock Holding History

EverSource Wealth Advisors’s Portfolio AARD Stock Details AARD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.46K Buy
774
+473
+157% +$2.21K ﹤0.01% 3342
2026
Q1 		$1.14K Buy
301
+241
+402% +$2.5K ﹤0.01% 3811
2025
Q4 		$788 Hold
60
– – ﹤0.01% 3771
2025
Q3 		$797 Buy
+60
New +$677 ﹤0.01% 3824

Other funds holding AARD

Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
AHL
Abel Hall LLC Baton Rouge, Louisiana $579M AUM 54.21% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HHCP
Hilton Head Capital Partners Hilton Head Island, South Carolina $198M AUM
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
FFO
Fortitude Family Office Scottsdale, Arizona $516M AUM 28.38% 1-Year Est. Return

EverSource Wealth Advisors's AARD Position: Q2 2026 in Review

EverSource Wealth Advisors increased its Aardvark Therapeutics (AARD) stake by 157% in Q2 2026, buying an estimated $2.21K and bringing the position to 774 shares worth $4.46K. The position accounts for ﹤0.01% of the portfolio, ranked #3342.

EverSource Wealth Advisors first reported a position in AARD in Q3 2025 and has held it in 4 quarters since. 13 funds tracked by Wall St. Rank hold AARD as of Q2 2026.

  • EverSource Wealth Advisors held 774 shares of Aardvark Therapeutics worth $4.46K as of Q2 2026.
  • EverSource Wealth Advisors bought 473 Aardvark Therapeutics shares in Q2 2026, an estimated $2.21K.
  • Aardvark Therapeutics made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #3342 holding.
  • EverSource Wealth Advisors first reported a position in Aardvark Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 13 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.